These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 29762872)

  • 1. The Effect of OnabotulinumtoxinA on Aura Frequency and Severity in Patients With Hemiplegic Migraine: Case Series of 11 Patients.
    Chen TY; Garza I; Dodick DW; Robertson CE
    Headache; 2018 Jul; 58(7):973-985. PubMed ID: 29762872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short and Mid-Term Predictors of Response to OnabotulinumtoxinA: Real-Life Experience Observational Study.
    Alpuente A; Gallardo VJ; Torres-Ferrús M; Álvarez-Sabin J; Pozo-Rosich P
    Headache; 2020 Apr; 60(4):677-685. PubMed ID: 32086801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for a separate type of migraine with aura: sporadic hemiplegic migraine.
    Thomsen LL; Ostergaard E; Olesen J; Russell MB
    Neurology; 2003 Feb; 60(4):595-601. PubMed ID: 12601098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine.
    Winner PK; Kabbouche M; Yonker M; Wangsadipura V; Lum A; Brin MF
    Headache; 2020 Mar; 60(3):564-575. PubMed ID: 32037549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential administration of peripheral nerve blocks and onabotulinumtoxinA for the treatment of chronic migraine and other headache disorders-A retrospective tolerability and safety study.
    Anderson CC; Iser CR; Hirte IL; Boddu S; Girardo ME; VanderPluym JH; Starling AJ
    Headache; 2024 Jun; 64(6):663-673. PubMed ID: 38700250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of clinical subtypes of migraine with aura.
    Eriksen MK; Thomsen LL; Olesen J
    Headache; 2006 Feb; 46(2):286-97. PubMed ID: 16492238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sporadic hemiplegic migraine.
    Thomsen LL; Olesen J
    Cephalalgia; 2004 Dec; 24(12):1016-23. PubMed ID: 15566415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis.
    Matharu M; Halker R; Pozo-Rosich P; DeGryse R; Manack Adams A; Aurora SK
    J Headache Pain; 2017 Dec; 18(1):78. PubMed ID: 28766236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population-based study of familial hemiplegic migraine suggests revised diagnostic criteria.
    Thomsen LL; Eriksen MK; Roemer SF; Andersen I; Olesen J; Russell MB
    Brain; 2002 Jun; 125(Pt 6):1379-91. PubMed ID: 12023326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Familial and sporadic hemiplegic migraine].
    Ducros A
    Rev Neurol (Paris); 2008 Mar; 164(3):216-24. PubMed ID: 18405771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
    Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single-center retrospective study of onabotulinumtoxinA for treatment of 245 chronic migraine patients: survey results of a real-world experience.
    Yalinay Dikmen P; Kosak S; Ilgaz Aydinlar E; Sagduyu Kocaman A
    Acta Neurol Belg; 2018 Sep; 118(3):475-484. PubMed ID: 29992442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of headache relief with cosmetic onabotulinumtoxinA injections.
    Goldman ND; Dorton LH; Marcum KK; Gilbert RM; Sandoval LF
    J Cosmet Dermatol; 2014 Sep; 13(3):224-31. PubMed ID: 25196690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study.
    Domínguez C; Pozo-Rosich P; Torres-Ferrús M; Hernández-Beltrán N; Jurado-Cobo C; González-Oria C; Santos S; Monzón MJ; Latorre G; Álvaro LC; Gago A; Gallego M; Medrano V; Huerta M; García-Alhama J; Belvís R; Leira Y; Leira R
    Eur J Neurol; 2018 Feb; 25(2):411-416. PubMed ID: 29171146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Features and Burden Scores in Japanese Pediatric Migraines With Brainstem Aura, Hemiplegic Migraine, and Retinal Migraine.
    Yamanaka G; Go S; Morichi S; Takeshita M; Morishita N; Suzuki S; Tomoko T; Kasuga A; Daida A; Ishida Y; Oana S; Suganami Y; Nagao R; Kashiwagi Y; Kawashima H
    J Child Neurol; 2020 Sep; 35(10):667-673. PubMed ID: 32476572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of flunarizine in childhood migraine: 11 years' experience, with emphasis on its effect in hemiplegic migraine.
    Peer Mohamed B; Goadsby PJ; Prabhakar P
    Dev Med Child Neurol; 2012 Mar; 54(3):274-7. PubMed ID: 22268377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Headache direction and aura predict migraine responsiveness to rimabotulinumtoxin B.
    Grogan PM; Alvarez MV; Jones L
    Headache; 2013 Jan; 53(1):126-136. PubMed ID: 23126597
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.